Showing 331-340 of 20873 results for "".
- Orforglipron: A New Oral GLP-1 Receptor Agonist in Type 2 Diabetes Carehttps://reachmd.com/news/orforglipron-a-new-oral-glp-1-receptor-agonist-type-2-diabetes-care/2475779/As the management of type 2 diabetes evolves, orforglipron is emerging as an oral GLP-1 receptor agonist with promising potential for efficacy and convenience. For many clinicians, the challenge of treating type 2 diabetes lies in delivering robust glycemic control while respecting p
- Orforglipron and Titrated Insulin Glargine in Type 2 Diabeteshttps://reachmd.com/news/orforglipron-titrated-insulin-glargine-t2d/2487416/Key Takeaways Greater HbA1c reductions were observed with each orforglipron dose than with placebo by week 40. Weight loss and smaller insulin dose increases were observed with orforglipron than with placebo by week 40. Clinically significant
- New Clues Into Hypoglycemia Awareness: Protein Levels May Signal Brain Adaptations in Type 1 Diabeteshttps://reachmd.com/news/new-clues-into-hypoglycemia-awareness-protein-levels-may-signal-brain-adaptations-in-type-1-diabetes/2484004/A recent proteomics study has identified a potential biomarker linked to impaired awareness of hypoglycemia (IAH), a dangerous complication of type 1 diabetes that leaves patients unable to sense when their blood glucose drops
- Optimizing Glycemic Control in COPD Patients with Type 2 Diabetes: Evolving Strategies for Better Outcomeshttps://reachmd.com/news/optimizing-glycemic-control-in-copd-patients-with-type-2-diabetes-evolving-strategies-for-better-outcomes/2475530/Managing Type 2 Diabetes in patients with chronic obstructive pulmonary disease demands a seamless integration of endocrinological and pulmonary care, as elevated blood glucose levels have b
- Ozempic May Lower Dementia Risk in People With Type 2 Diabetes, Study Findshttps://reachmd.com/news/ozempic-may-lower-dementia-risk-in-people-with-type-2-diabetes-study-finds/2467565/Semaglutide, the main active ingredient in Ozempic, is linked to a lower risk of cognitive decline in a new study. The study only focused on patients with type 2 diabetes. Doctors say there may be something to this.
- FINE‑ONE: Finerenone Lowers Albuminuria But Raises Hyperkalemia in Type 1 Diabetes CKDhttps://reachmd.com/news/fineone-finerenone-lowers-albuminuria-but-raises-hyperkalemia-in-type-1-diabetes-ckd/2485964/A phase 3 abstract reports results of finerenone in adults with type 1 diabetes and chronic kidney disease, focusing on changes in albuminuria alongsid
- Rising Challenge: Early-Onset Type 2 Diabetes in Young Adults and Emerging Technologieshttps://reachmd.com/news/rising-challenge-early-onset-type-2-diabetes-in-young-adults-and-emerging-technologies/2475646/Rates of early-onset type 2 diabetes among young adults have nearly doubled globally; in Sweden, recent studies observ
- Night Owls Are More Likely to Develop Type 2 Diabetes – And It’s Not Just Because of an Unhealthy Lifestyle, Dutch Study Findshttps://reachmd.com/news/night-owls-are-more-likely-to-develop-type-2-diabetes-and-its-not-just-because-of-an-unhealthy-lifestyle-dutch-study-finds/2468140/Night owls have a higher BMI, larger waists, more hidden body fat and are almost 50% more likely to develop type 2 diabetes (T2D) than those who go to bed earlier, new research to be presented at the Annual Meeting of the European Association fo
- Few Patients Can Treat Their Type 2 Diabetes Through Weight Loss Alonehttps://reachmd.com/news/few-patients-can-treat-their-type-2-diabetes-through-weight-loss-alone/2456962/Sign up for a full digest of all the best opinions of the week in our Voices Dispatches emailSign up to our free weekly Voices newsletterVery few patients diagnosed with type 2 diabetes are able to treat their c
- Adenosine Signaling and Metabolic Regulation: Exploring Obesity-Driven Type 2 Diabeteshttps://reachmd.com/news/adenosine-signaling-and-metabolic-regulation-exploring-obesity-driven-type-2-diabetes/2474708/Recent advancements in Diabetes and Endocrinology have illuminated the critical function of adenosine receptor-mediated pathways. Through investigating mechanisms like ATP catabolism and receptor-mediated regulation, researchers have identified interactions between